AB
Highly rated in
26
conditions
Highly rated in
26
conditions
Check Dr. Andrew Berchuck's experience treating your condition:
About Dr. Andrew Berchuck

Andrew Berchuck is an Oncologist and an Obstetrics and Gynaecologist in Durham, North Carolina. Berchuck is highly rated in 26 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Endometrial Cancer, Tubal Ligation, and Hormone Replacement Therapy. He is licensed to treat patients in North Carolina. Berchuck is currently accepting new patients.

His clinical research consists of co-authoring 256 peer reviewed articles and participating in 2 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Andrew Berchuck it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Andrew Berchuck accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
  •  Cigna
  •  UnitedHealthcare
  •  Aetna
View 1 More Insurance +

Call to see if your plan is accepted.
Locations
2301 Erwin Rd, Durham, NC 27705
Other Locations
1236 Huffman Mill Rd, Suite 120, Burlington, NC 27215
Background & Education
Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynaecology
Licenses
Obstetrics & Gynecology in NC
Hospital Affiliations
Cone Health Alamance Regional Medical Center
Duke University Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


2 Clinical Trials

Tissue and Data Acquisition Activity for the Study of Gynecological Disease
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
View 1 Less Clinical Trial -

256 Total Publications

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors